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Abstract: 
Data on stroke, mortality and associated comorbidities in elderly atrial 
fibrillation (AF) patients in Japan may differ from Western countries. There 
has never been a systematic comparison between stroke risk profiles and 
outcomes amongst community-based elderly patients with AF in Japan and 
the United Kingdom (UK).  
Objective and Methods: We compared clinical characteristics, stroke risk 
and outcomes amongst elderly AF patients from the Fushimi AF Registry 
(Japan; N=1791) and the Darlington AF registry (UK; N=1338).  
Results:  The Fushimi cohort had a mean age 81.8 years and CHA2DS2-
VASc score 4.3(1.4), whereas the Darlington cohort had a mean age 
83.6(5.7) years and CHA2DS2-VASc score 4.4(1.4). Over a 12 month 
follow-up period, observed stroke and mortality rates in Fushimi were 
3.4%(n=61) and 11.5%(n=206), whilst corresponding event rates in the 
Darlington cohort were 4.4%(n=59) and 14.1%(n=188), respectively. 
Appropriate use of oral anticoagulation (OAC, essentially vitamin K 
antagonist) was <60% in both registries.  
On multivariable analysis, ethnicity (Japan vs.UK) was neither associated 
with the risk of stroke (Odds Ratio[OR] 0.92, 95%CI 0.63-1.36; p=0.69) 
nor death(OR 0.92, 95%CI 0.80-1.27; p=0.92). In a subgroup analysis of 
elderly patients not receiving OAC(n=1489), a prior history of stroke was 
associated with the risk of stroke(OR 2.42; 95%CI 1.39–4.12; p=0.002), 
https://mc.manuscriptcentral.com/heart
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but not ethnicity(OR 0.86; 95%CI 0.50-1.47; p=0.58).  
Conclusions:  Elderly(age≥75) AF patients in both Japan and the UK are at 
similarly high risk of stroke and death, with OAC still under-utilised in both 
populations. Ethnicity was not independently associated with the risk of 
stroke, regardless of OAC use or non-use.  
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 3 
Abstract  
Background: Data on stroke, mortality and associated comorbidities in elderly atrial 
fibrillation (AF) patients in Japan may differ from Western countries. There have been few 
systematic comparisons between stroke risk profiles and outcomes amongst community-
based elderly (aged ≥75) patients with AF in Japan and the United Kingdom (UK).  
Objective and Methods: We compared clinical characteristics, stroke risk and outcomes 
amongst elderly AF patients from the Fushimi AF Registry (Japan; N=1791) and the 
Darlington AF registry (UK; N=1338). 
Results:  The Fushimi cohort had a mean age 81.8 (SD 5.3) years and CHA2DS2-VASc score 4.3 
(1.4), whereas the Darlington cohort had a mean age 83.6 (5.7) years and CHA2DS2-VASc 
score 4.4 (1.4). Over a 12 month follow-up period, observed stroke and mortality rates in 
Fushimi were 3.4% (n=61) and 11.5% (n=206), whilst corresponding event rates in the 
Darlington cohort were 4.4% (n=59) and 14.1% (n=188), respectively. Appropriate use of 
oral anticoagulation (OAC, essentially a vitamin K antagonist) was <60% in both registries.  
On multivariable analysis, ethnicity (Japan vs. UK) was neither associated with the risk of 
stroke (Odds Ratio [OR] 0.92, 95%CI 0.63-1.36; p=0.69) nor death (OR 0.92, 95%CI 0.80-1.27; 
p=0.92). In a subgroup analysis of elderly patients not receiving OAC (n=1489), a prior 
history of stroke was associated with the risk of stroke (OR 2.42; 95%CI 1.39–4.12; p=0.002), 
but not ethnicity (OR 0.86; 95%CI 0.50-1.47; p=0.58).  
Conclusions:  Elderly (age≥75) AF patients in both Japan and the UK are at similarly high risk 
of stroke and death, with OAC still under-utilised in both populations. Ethnicity was not 
independently associated with the risk of stroke, regardless of OAC use or non-use. 
 
Keywords     Ethnicity, Stroke, Death, Aged, Atrial fibrillation  
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 4 
KEY MESSAGES  
What is already known about this subject?  
Data on stroke, mortality and associated comorbidities in elderly atrial fibrillation (AF) 
patients in Asia may differ from Western countries. There is the perception that risk factors 
for stroke and outcomes amongst Japanese patients with AF may differ from those in 
Western countries. 
 
What does this study add? 
Both Japan and UK cohorts are at similarly high risk of stroke and death. Oral 
anticoagulation (OAC) was under-utilised (<60%) in both populations, despite a lower risk of 
death being significantly associated with OAC use. Ethnicity (Japanese vs. British) was not 
independently associated with the risk of stroke regardless of whether or not OAC was used. 
 
How might this impact on clinical practice?  
Our results can inform specific guidance on the implications of different stroke risks and 
profiles in Asians vs Caucasians, and highlight considerable gaps between AF treatment 
guidelines and clinical practice in Asians as well as Caucasians, in particular, the underuse of 
OAC.  Moreover, the perception that individuals of Asian ethnicity are at higher risk of 
stroke than Caucasians should be reconsidered given that our results demonstrate no 
obvious ethnic difference between Asians and Caucasians in the risk of stroke. 
 
 
Page 5 of 28
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 5 
Introduction 
 
Age is an important determinant of stroke risk in atrial fibrillation (AF), which independently 
increases the risk by 1.5-fold per decade of life among patients with AF.
1
   Nonetheless, data 
on stroke and thromboembolism in elderly patients in Japan are limited, which is important 
given the increasing elderly age profile of the general population in Japan. Furthermore, 
there is the perception that risk factors for stroke and outcomes amongst Japanese patients 
with AF may differ from those in Western countries.  However, there have been few 
systematic comparisons between risk profiles and outcomes amongst community-based 
elderly (age >75) patients with AF in Japan and United Kingdom (UK). 
2
 
 
To investigate this further, we used the Fushimi AF Registry as a Japanese community-based 
population and the Darlington AF registry as a UK community-based population to evaluate 
ethnic differences in clinical characteristics, stroke risk profiles and outcomes amongst 
elderly AF patients in Japan and the UK. 
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 6 
Methods 
 
The design of Fushimi AF Registry has been previously described.  
3
 
4
  In brief, the Fushimi AF 
Registry is a community-based prospective survey of AF patients in Fushimi-ku, Kyoto. 
Fushimi-ku is densely populated with a total population of 283,000, and is assumed to 
represent a typical urban community in Japan. A total of 79 institutions, all of which are 
members of Fushimi-Ishikai (Fushimi Medical Association), participated in the registry. The 
enrolment of patients started in March 2011. A total of 3,499 patients were enrolled by 
April 2014, with 51% being aged >75 (n=1,791) and 100% were Japanese.  The Fushimi AF 
Registry (UMIN Clinical Trials Registry: UMIN000005834) protocol was approved by the 
ethical committees of the National Hospital Organization Kyoto Medical Center and Ijinkai 
Takeda General Hospital.   
 
The design of the Darlington AF registry has also been described previously.
5
 In brief, the 
study population was derived from all 105,000 patients who were registered at one of 11 
general practices serving the town of Darlington. All patients whose vital status in March 
2013 was known were eligible for inclusion.  A total of 2,259 (2.15%) patients with AF were 
identified (59% were aged >75, n=1338), using the Guidance on Risk Assessment in Stroke 
Prevention for Atrial Fibrillation (GRASP-AF) tool 
6
 and are included in this analysis.  
According to the last Census data in the Darlington cohort, more than 96% of the Darlington 
population were Caucasian. For the Darlington registry, ethical approval was not required 
under United Kingdom National Health Service research governance arrangements for the 
project. 
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 7 
Baseline clinical characteristics of the subjects entered in the Fushimi AF Registry and 
Darlington AF Registry have also been reported elsewhere.
3 5
  Patients were categorised 
according to the CHA2DS2-VASc scores (Congestive heart failure, Hypertension, Age ≥ 75 
years [double], Diabetes mellitus, previous thromboembolism [double], Vascular disease, 
Age 65–74 years, and female gender). The primary endpoints in the present analysis were 
the incidence of stroke and all-cause death during the follow-up period. In the present study, 
we used the data of all patients with obtainable follow-up information in the Fushimi AF 
Registry, and those registered in the Darlington AF registry. We extracted and compared the 
data of elderly AF patients (aged≥75) from both registries.  
 
Differences in the methods of data collection among the two databases were seen. The 
Darlington AF Registry was a completed study that dealt with a closed cohort and had 100% 
follow-up data. In contrast, the Fushimi AF Registry was an on-going cohort, with enrolment 
on-going at the time of the present analyses. Therefore, to ensure an equivalent period for 
the two databases, we analysed the follow-up data at 12 months. 
 
Statistical analysis 
Categorical and continuous patient data are presented as number (%) and mean ± SD, 
respectively. The incidence of ischemic stroke was presented as actual number and 
percentages of patients according to the CHA2DS2-VASc scores.  Multivariate logistic 
regression analysis was performed to determine the independent risk factors for ischemic 
stroke and all-cause death after adjusted for components of the CHA2DS2-VASc score (age 
assessed as a continuous variable) and use of antithrombotic agents.  The relatively 
homogeneous ethnicity make-up of the two registry cohorts allows inter-ethnic 
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 8 
comparisons. All statistical analysis was done using SPSS 21(SPSS, Chicago, IL, USA). 
Statistical significance was set at a 2-sided P<0.05.  
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 9 
Results 
 
The Fushimi cohort (n=1,791) had a mean (standard deviation [SD]) age 81.8 (5.3) years and 
CHA2DS2-VASc score 4.3 (1.4), whereas the Darlington cohort (n=1,338) had a mean (SD) age 
83.6 (5.7) years and CHA2DS2-VASc score 4.4 (1.4). (Table 1, Figure 1)  The appropriate use of 
oral anticoagulation (OAC) was <60% in both registries despite all patients being at a high 
risk of stroke (i.e., CHA2DS2-VASc score≥2). 
 
Over a 12 month follow-up period, observed stroke and mortality rates in Fushimi were 
3.4% (n=61) and 11.5% (n=206), whilst corresponding event rates in the Darlington cohort 
were 4.4% (n=59) and 14.1% (n=188), respectively. The distribution of outcomes, stroke and 
death, in both registries is described according to CHA2DS2-VASc score in Figure 2, where the 
patterns were broadly comparable.   
 
Figure 3 demonstrates that the proportion of patients receiving OAC varied by stroke risk 
from 46% with a CHA2DS2-VASc score of 2, to 76% with a CHA2DS2-VASc of 8 in Fushimi, 
whereas in Darlington, from 43% with a CHA2DS2-VASc score of 2, to 50% with a CHA2DS2-
VASc of 8.  Significant differences were seen in the proportion of patients receiving 
combination OAC and antiplatelet therapy (APT), and APT alone, both of which rose with 
increasing CHA2DS2-VASc score in the Fushimi cohort, whereas the proportion receiving 
combination OAC and APT in the Darlington cohort was under 10%, while the proportion on 
APT alone was as high as 40% across all CHA2DS2-VASc scores.  The proportion not receiving 
any antithrombotic therapy was relatively high among patients with a lower CHA2DS2-VASc 
score in Fushimi when compared with those in Darlington cohort. 
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On multivariable logistic regression analysis (Table 2), an increased risk of stroke was 
independently associated with previous stroke (Odds Ratio [OR] 2.96, 95%CI 2.01-4.35; 
p<0.001), but not ethnicity (OR 0.92, 95%CI 0.63-1.36; p=0.69).  
A lower risk of death was independently associated with OAC use (OR 0.53, 95%CI 0.41-0.67; 
p<0.001) and positively associated with age (OR 1.10, 95%CI 1.08-1.12; p<0.001) and heart 
failure (OR 1.71, 95%CI 1.35-2.15; p<0.001), previous stroke (OR 1.33, 95%CI 1.03-1.71; 
p=0.03) and vascular disease (OR 2.14, 95%CI 1.63-2.79; p<0.001).   
 
Sub-group analysis 
A sub-group analysis of 1,489 elderly patients (aged≥75) without OAC use, from the Fushimi 
AF Registry (n=798) and the Darlington AF Registry (n=691), was performed. In the Fushimi 
AF registry, mean (SD) age was 82.9 (5.9) years and mean (SD) CHA2DS2-VASc score was 4.2 
(1.3).   Corresponding figures for the Darlington AF registry were 85.0 (6.0) years and 4.3 
(1.4), respectively (Supplemental Table I).   
 
Among these patient, 65 patients experienced stroke (n=31; 3.9%/year in Fushimi vs. n=34; 
4.9%/year in Darlington) over the 12 month follow-up period. The incidence of all-cause 
mortality was 15.5% (n=124) in Fushimi and 19.4% (n=134) in Darlington (Supplemental 
Table II). 
 
On multivariable analysis of the sub-group data, a history of stroke (OR 2.42; 95%CI 1.39–
4.12; p=0.002) was associated with the risk of stroke, but not ethnicity (Japan vs. UK) (OR 
0.86; 95%CI 0.50-1.47; p=0.58) [Table 3]. The risk of death was independently associated 
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with age (OR 1.10; 95%CI 1.07-1.13; p<0.001), heart failure (OR 1.64; 95%CI 1.20-2.24; 
p=0.002), a history of stroke (OR 1.62; 95%CI 1.14-2.27; p=0.01) and vascular disease (OR 
2.36; 95%CI 1.64-3.37; p<0.001) but was lowered with use of antiplatelet agents (OR 0.39; 
95%CI 0.28-0.54; p<0.001), and with Japanese ethnicity (Japan vs. UK) (OR 0.67; 95%CI 0.49-
0.92; p=0.01).    
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 12
Discussion 
 
In this analysis, which compared elderly (age≥75) AF patients in both Japan and the UK for 
the first time, both registry cohorts are at similarly high risk of stroke and death. Second, 
OAC was under-utilised (<60%) in both populations, despite a lower risk of death being 
significantly associated with OAC use. Third, ethnicity (Japanese vs. British) was not 
independently associated with the risk of stroke after adjustment for potential confounders 
that could influence the risk of events regardless of whether or not OAC was used. 
 
Ethnic differences    
The age-adjusted prevalence of AF may be lower among Asians than among Caucasians. 
7
 
However, the risk of stroke and systemic embolism for warfarin-anticoagulated AF Asian 
patients appears higher compared to non-Asians, though Asians had similar mean stroke 
risk scores. 
8 9
  
 
In the present comparative study, the incidence of stroke in elderly patients (aged≥75) in 
Japan was 3.4% and 4.4% in the UK. In sub-group analysis of elderly patients not receiving 
OAC, the same trends were found (3.9% in Japan vs. 4.9% in the UK). Importantly, 
multivariable analysis showed that ethnicity was not independently associated with the risk 
of stroke, after adjustment for potential confounders (i.e., the components of CHA2DS2-VASc 
score). Thus, there is no obvious racial difference between Japan and the UK in the risk of 
stroke amongst elderly AF patients. 
 
Current use of antithrombotic therapy 
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 13
In recent years in Japan, prescription of warfarin has increased up to approximately 73% 
without any gender differences.
10,11
 The high rate of warfarin use in these cohorts may 
reflect the participation in the selected institutions with cardiologists who are more familiar 
with anticoagulation treatment in AF. In the present community based study, OAC therapy 
was still underutilised (<60%) in both Japanese and British elderly populations. The risks are 
probably multifactorial, perhaps reflecting a perception that elderly patients with AF have 
carry a relatively higher risk of major bleeding, but the relative benefits/harms of oral 
anticoagulation for stroke or mortality and major bleeding showed consistency despite 
increasing age strata in a real-world and clinical trial setting.
12 13
   
 
Recent clinical trials
14
 
15
  and guidelines
16
 may also have contributed to the decrease in the 
use of antiplatelet agents in Fushimi registry. Nonetheless, about 40% of patients at high 
risk of stroke were still receiving antiplatelet monotherapy in the Darlington registry.  
Although the present analysis did not capture the reasons for withholding antithrombotic 
therapy, other registries 
17
 found that more than half of reasons reported were based on 
physician choice (that is, fears over the risk of bleeding and/or falls, worries over patient 
adherence). A recent analysis of elderly patients from the UK General Practice Research 
Database (GPRD) 
18
 suggested that the under-utilisation of OAC among this group was not a 
result of bleeding risk or comorbidities. Therefore, this may highlight the importance of 
determining individual stroke and bleeding risk and discussing treatment options with 
patients, prior to considering OAC therapy in elderly patients.  
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Limitations 
First, our study showed the risk of death was inversely related to OACs use, but this might 
be reflected by the fact that OACs were unlikely to be used in patients with poorer general 
health status (i.e., shorter life expectancy).  The aspirin effect may be due to the reduction 
of cardiovascular disease morbidity and mortality (where aspirin has some benefit overall, 
albeit modest), rather than stroke/thromboembolism reduction (where aspirin has virtually 
no beneficial effect)
19
.  This small mortality effect of aspirin (but with no impact on stroke) 
was also seen recently in a paper from the Danish registries
20
.  In addition, OAC treatment in 
the randomised trials is associated with a significant reduction in all cause mortality (by 
26%), compared to placebo or control
21
.  Second, despite adjustment for various risk factors, 
there remains the potential for residual confounding. For instance, a significant association 
between ethnicity and death in the pooled sub-group analysis may be the result of 
confounding that cannot be mitigated by statistical adjustment. The fact that patients in 
Japanese population are younger than those in the UK may have a beneficial impact on 
mortality in these populations. Third, compared with the UK patients, the use of 
combination therapy of OAC with antiplatelet agents was three fold higher in Japanese 
patients. Although OACs are recommended as effective stroke prevention in routine clinical 
practice in Japan, anti-platelet drugs are likely to be overused. 
4
   No comparative data are 
available on the bleeding risk of the 2 cohorts due to the lack of data on bleeding 
complications in the UK registry, and further inter-ethnic studies are needed to investigate 
the association between the use of combination therapy and bleeding risks in different 
ethnic groups. 
 Fourth, data regarding warfarin control level (i.e., time in therapeutic range) was not 
available in the Darlington registry during the follow-up period. Thus, to exclude the 
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possible influence of OAC use on outcomes, we performed the sub-group analysis in 
patients not receiving OAC, and evaluated racial difference between Japan and the UK in the 
risk of stroke.  Fifth, even though Fushimi-ku and Darlington regions are relatively densely 
populated urban areas, and is assumed to represent a typical urban community in their 
respective countries, the results in each region cannot completely represent that situation 
in the 2 countries as a whole.  Last, the present analysis did not capture the reasons for 
withholding antithrombotic therapy, bleeding problems or compliance issues. These may 
potentially be linked to the incidence of stroke and worsening prognosis. 
 
In conclusion, elderly (age≥75) AF patients in both Japan and the UK are at similarly high risk 
of stroke and death, but OAC is still under-utilised in both populations. Ethnicity was not 
independently associated with the risk of stroke in elderly AF patients, regardless of 
whether OAC was used or not.  
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Figure legends 
 
Figure 1: CHA2DS2-VASc score distribution between patients with atrial fibrillation in Japan 
and the United Kingdom  
Figure 2: Stroke and death rate over 1 year follow-up for patients with atrial fibrillation in 
Japan and the United Kingdom 
Figure 3: Anti-thrombotic therapies in patients with atrial fibrillation by CHA2DS2-VASc score 
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Table 1: Patient characteristics and current use of anti-thrombotic therapies in the Japanese 
and United Kingdom cohorts 
 
 Fushimi AF 
registry 
(Japan) 
Darlington AF 
registry 
(UK) 
P value 
Total  (n=) 1791 1338  
Mean (SD) Age, years 81.8 (5.3) 83.6 (5.7) <0.01 
Female (%) 887 (49.5) 739 (55.2) <0.01 
Hypertension (%) 1141 (63.7) 934 (69.8) <0.01 
Diabetes Mellitus (%) 400 (22.3) 288 (21.5) 0.59 
Heart failure (%) 600 (33.5) 351 (26.2) <0.01 
Previous stroke (%) 424 (23.7) 307 (22.9) 0.63 
Vascular disease (%) 215 (12.0) 270 (20.2) <0.01 
Mean (SD) CHADS2 score 2.7 (1.2) 2.6 (1.2) 0.43 
Mean (SD) CHA2DS2-VASC 
score 
4.3 (1.4) 4.4 (1.4) 0.03 
Medication    
Oral anticoagulants  993 (55.4) 647 (48.4) <0.01 
- Vitamin K antagonist 902 (50.4) 634 (47.4) 0.10 
- Non-vitamin K 
antagonist 
91 (5.1) 13 (1.0) <0.01 
Antiplatelet agents  597 (33.3) 585 (43.7) <0.01 
Combination use of Oral 
anticoagulants and 
Antiplatelet agents 
270 (15.1) 63 (4.7) <0.01 
 
No antithrombotic agents 471 (26.3) 169 (12.6) <0.01 
SD, standard deviation; UK, United Kingdom; AF, atrial fibrillation 
CHADS2 score, Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and 
previous stroke/transient ischemic attack (double); 
CHA2DS2-VASc score, Congestive heart failure, Hypertension, Age ≥ 75 years (double), 
Diabetes mellitus, previous thromboembolism (double), Vascular disease, Age 65–74 years, 
and female gender 
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Table 2: Multivariate logistic regression analysis for stroke and death  
 
 Stroke  Death  
 OR (95%CI) P value OR (95%CI) P value 
Age 1.03 (0.99-1.06) 0.11 1.10 (1.08-1.12) <0.001 
Female 1.36 (0.91-2.04) 0.13 1.02 (0.81-1.29) 0.86 
Heart failure 0.97 (0.63-1.46) 0.88 1.71 (1.35-2.15) <0.001 
Hypertension 1.26 (0.83-1.94) 0.29 0.90 (0.71-1.14) 0.36 
Diabetes mellitus 1.21 (0.77-1.84) 0.40 1.12 (0.85-1.45) 0.42 
Previous stroke 2.96 (2.01-4.35) <0.001 1.33 (1.03-1.71) 0.03 
Vascular disease 1.24 (0.74-1.99) 0.41 2.14 (1.63-2.79) <0.001 
Use of oral 
anticoagulation 
 
0.69 (0.46-1.02) 0.06 0.53 (0.41-0.67) <0.001 
Ethnicity*  
(Japan vs UK) 
 
0.92 (0.63-1.36) 0.69 1.01 (0.80-1.27) 0.92 
 
* UK as a reference 
OR, Odds Ratio; CI, Confidence Interval; UK, United Kingdom  
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Table 3: Multivariate logistic regression analysis for stroke and death in patients not 
receiving oral anticoagulation (n=1489; Japan from Fushimi AF Registry [n=798] and the UK 
from Darlington AF Registry [n=691]) 
 
 
 
 Stroke  Death  
 OR (95%CI) P value OR (95%CI) P value 
Age 0.99 (0.95-1.03) 0.68 1.10 (1.07-1.13) <0.001 
Female 1.59 (0.93-2.79) 0.09 1.10 (0.81-1.49) 0.54 
Heart failure 1.04 (0.57-1.83) 0.89 1.64 (1.20-2.24) 0.002 
Hypertension 1.53 (0.87-2.84) 0.14 0.81 (0.60-1.10) 0.18 
Diabetes mellitus 1.47 (0.82-2.53) 0.19 1.17 (0.81-1.65) 0.40 
Previous stroke 2.42 (1.39-4.12) 0.002 1.62 (1.14-2.27) 0.01 
Vascular disease 1.29 (0.65-2.39) 0.45 2.36 (1.64-3.37) <0.001 
Use of antiplatelet agents 1.20 (0.68-2.15) 0.54 0.39 (0.28-0.54) <0.001 
Ethnicity*  
(Japan vs UK) 
0.86 (0.50-1.47) 0.58 0.67 (0.49-0.92) 0.01 
* UK as a reference 
OR, Odds Ratio; CI, Confidence Interval; UK, United Kingdom 
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STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No Recommendation 
PAGE 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
1 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
3 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
4 
Objectives 3 State specific objectives, including any prespecified hypotheses 4 
Methods  
Study design 4 Present key elements of study design early in the paper 5 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
5 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources 
and methods of selection of participants. Describe methods of 
follow-up 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
5 
(b) Cohort study—For matched studies, give matching criteria 
and number of exposed and unexposed 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
5-6 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
5-6 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group 
5-6 
Bias 9 Describe any efforts to address potential sources of bias  
Study size 10 Explain how the study size was arrived at   
Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
6 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
6 
(b) Describe any methods used to examine subgroups and 
interactions 
6 
(c) Explain how missing data were addressed  
(d) Cohort study—If applicable, explain how loss to follow-up  
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was addressed 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
(e) Describe any sensitivity analyses  
Continued on next page
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Results Page  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
7  
(b) Give reasons for non-participation at each stage   
(c) Consider use of a flow diagram   
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
7  
(b) Indicate number of participants with missing data for each variable of 
interest 
  
(c) Cohort study—Summarise follow-up time (eg, average and total 
amount) 
  
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures 
over time 
7  
Case-control study—Report numbers in each exposure category, or 
summary measures of exposure 
  
Cross-sectional study—Report numbers of outcome events or summary 
measures 
  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
7-8  
(b) Report category boundaries when continuous variables were categorized   
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
  
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
  
Discussion   
Key results 18 Summarise key results with reference to study objectives 10  
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
12  
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
12  
Generalisability 21 Discuss the generalisability (external validity) of the study results 12  
Other information   
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is 
based 
1  
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
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